We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

164 hedge funds and large institutions have $1.02B invested in Corvus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 55 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

185% more capital invested

Capital invested by funds: $359M → $1.02B (+$665M)

172% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 25

158% more call options, than puts

Call options by funds: $21M | Put options by funds: $8.14M

83% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 30

32% more funds holding

Funds holding: 124 → 164 (+40)

20.94% more ownership

Funds ownership: 62.51% → 83.45% (+21%)

Holders
164
Holders Change
+40
Holders Change %
+32.26%
% of All Funds
2.02%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.06%
New
68
Increased
55
Reduced
30
Closed
25
Calls
$21M
Puts
$8.14M
Net Calls
+$12.9M
Net Calls Change
+$13.2M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$46M
2
DTC
Deep Track Capital
Connecticut
+$39.8M
3
CC
Commodore Capital
New York
+$36M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$32M
5
B
Braidwell
Connecticut
+$28M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$22.1M
2
Morgan Stanley
Morgan Stanley
New York
-$17.1M
3
MB
MPM BioImpact
Massachusetts
-$17.1M
4
ACM
ADAR1 Capital Management
Texas
-$6.03M
5
Jane Street
Jane Street
New York
-$5.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
151
PNC Financial Services Group
Pennsylvania
$2K – – –
S
152
SignatureFD
Georgia
$1.99K +$958 +60 +79%
FFO
153
Fortitude Family Office
Arizona
$1.45K +$1.58K +99 New
Royal Bank of Canada
154
Royal Bank of Canada
Ontario, Canada
$1K -$24.6K -1,543 -95%
LFG
155
Larson Financial Group
Missouri
$951 +$1.04K +65 New
AF
156
Allworth Financial
California
$908 +$718 +45 +265%
CA
157
Clearstead Advisors
Ohio
$732 -$2.44K -153 -75%
FFA
158
Farther Finance Advisors
California
$563 -$4.53K -284 -88%
SFS
159
Sunrise Financial Services
Washington
$439 +$479 +30 New
VCM
160
Versant Capital Management
Arizona
$410 +$447 +28 New
Fifth Third Bancorp
161
Fifth Third Bancorp
Ohio
$307 +$335 +21 New
MCM
162
MAI Capital Management
Ohio
$103 +$112 +7 New
TPWA
163
Twin Peaks Wealth Advisors
California
$102 +$112 +7 New
ASN
164
Advisory Services Network
Georgia
$15 +$16 +1 New
Point72 Asset Management
165
Point72 Asset Management
Connecticut
– -$22.1M -2,875,000 Closed
RI
166
RTW Investments
New York
– -$3.45M -447,607 Closed
EWM
167
Empirical Wealth Management
Washington
– -$1.29M -167,400 Closed
FAM
168
Fred Alger Management
New York
– -$1.11M -144,381 Closed
ECM
169
ExodusPoint Capital Management
New York
– -$668K -86,720 Closed
NIM
170
NEOS Investment Management
Connecticut
– -$623K -80,893 Closed
D.E. Shaw & Co
171
D.E. Shaw & Co
New York
– -$500K -64,915 Closed
HSBC Holdings
172
HSBC Holdings
United Kingdom
– -$451K -59,269 Closed
CM
173
Caption Management
Oklahoma
– -$787K -49,325 Closed
A
174
AlphaQuest
New York
– -$277K -35,972 Closed
AA
175
Argent Advisors
Louisiana
– -$231K -30,000 Closed
4 5 6
7
8

CRVS Hedge Fund Activity: Q1 2026 in Review

164 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2026, worth a combined $1.02B — up 185% from $359M a quarter earlier.

Buyers outnumbered sellers: 68 funds opened new CRVS positions and 25 closed out — a net gain of 43 holders — while 55 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $46M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $22.1M sold.

  • 164 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2026, up from 124 in Q4 2025.
  • Funds reported $1.02B of Corvus Pharmaceuticals stock for Q1 2026, up 185% quarter-over-quarter.
  • 68 funds opened new Corvus Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +43 holders.
  • The largest Corvus Pharmaceuticals buyer in Q1 2026 was T. Rowe Price Associates, an estimated $46M added.
  • The largest Corvus Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $22.1M sold.

Based on aggregated 13F filings for Q1 2026.